GIANT PIGMENTED HAIRY NEVUS
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.
|
23392294 |
2013 |
GIANT PIGMENTED HAIRY NEVUS
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.
|
18633438 |
2009 |
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
UNIPROT |
|
|
|
Colorectal Carcinoma
|
|
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
GIANT PIGMENTED HAIRY NEVUS
|
|
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
MYELODYSPLASTIC SYNDROME
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Lymphoma, Non-Hodgkin, Familial
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Gastric Adenocarcinoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Cutaneous Melanoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Transitional cell carcinoma of bladder
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Medulloblastoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Multiple Myeloma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Colorectal Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Stomach Neoplasms
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.
|
22962325 |
2012 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
|
20179705 |
2010 |
melanoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
|
18390968 |
2008 |